Oxford Square Capital Corporation (OXSQZ) News

Form PRE 14A - Other preliminary proxy statements

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Exicure, Inc. Reports Full Year 2023 Financial Results

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting...

Form 8-K - Current report

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]